Host immunity modulates the efficacy of microbiota transplantation for treatment of Clostridioides difficile infection.
Eric R LittmannJung-Jin LeeJoshua E DennyZahidul AlamJeffrey R MaslankaIsma ZarinRina MatsudaRebecca A CarterBože SusacMiriam S SaffernBryton FettLisa M MatteiKyle BittingerMichael C AbtPublished in: Nature communications (2021)
Fecal microbiota transplantation (FMT) is a successful therapeutic strategy for treating recurrent Clostridioides difficile infection. Despite remarkable efficacy, implementation of FMT therapy is limited and the mechanism of action remains poorly understood. Here, we demonstrate a critical role for the immune system in supporting FMT using a murine C. difficile infection system. Following FMT, Rag1 heterozygote mice resolve C. difficile while littermate Rag1-/- mice fail to clear the infection. Targeted ablation of adaptive immune cell subsets reveal a necessary role for CD4+ Foxp3+ T-regulatory cells, but not B cells or CD8+ T cells, in FMT-mediated resolution of C. difficile infection. FMT non-responsive mice exhibit exacerbated inflammation, impaired engraftment of the FMT bacterial community and failed restoration of commensal bacteria-derived secondary bile acid metabolites in the large intestine. These data demonstrate that the host's inflammatory immune status can limit the efficacy of microbiota-based therapeutics to treat C. difficile infection.
Keyphrases
- clostridium difficile
- oxidative stress
- healthcare
- gene expression
- cancer therapy
- machine learning
- small molecule
- metabolic syndrome
- immune response
- transcription factor
- cell proliferation
- genome wide
- regulatory t cells
- drug delivery
- skeletal muscle
- mesenchymal stem cells
- bone marrow
- cell cycle arrest
- dendritic cells
- signaling pathway
- adipose tissue
- electronic health record
- deep learning
- catheter ablation
- atrial fibrillation
- big data
- hematopoietic stem cell